FAST ACHIEVEMENT AND/OR COMPLETION OF SUBSTANTIAL STABLE DRUG DELIVERY Russian patent published in 2015 - IPC A61M5/00 A61K38/26 A61K9/66 A61P3/10 

Abstract RU 2547990 C2

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy and endocrinology, and can be used in treating patients suffering type 2 diabetes mellitus. That is ensured by a continuous exenatide delivery by implanting into a patient into an osmotic delivery device comprising an impermeable container, a semi-permeable membrane, an osmotic mechanism integrated into the container and adjoining the semi-permeable membrane, a piston adjoining the above osmotic mechanism; the above piston forms a movable seal with an inner surface of the container and divides the container into a first chamber comprising the osmotic mechanism, and a second chamber comprising a suspension formulation, and a diffusion adjustor. The suspension formulation contains a particle formulation containing exenatide particles having a diameter of less than 10 to 30 mcm. The delivery formulation contains a solvent specified in a group consisting of benzyl benzoate, lauryl lactate and lauryl alcohol, and polyvinylpyrrolidone polymer. The delivery formulation has a viscosity of approximately 10,000 poise to approximately 20,000 poise at 37°C. The continuous exenatide delivery in the therapeutic concentration is ensured for 5 days or less. The continuous exenatide delivery from the osmotic delivery device in a dose of exenaide of 10 mcg/day, 20 mcg/day, 30 mcg/day, 40 mcg/day, 60 mcg/day, and 80 mcg/day can be effected through at least three months.

EFFECT: method enables the effective treatment of the given pathology by the fast achievement and long maintenance of the exenatide concentration to be completed rapidly with no constant injections or oral administration.

15 cl, 20 tbl, 21 dwg, 4 ex

Similar patents RU2547990C2

Title Year Author Number
FAST ACHIEVEMENT AND/OR TERMINATION OF SIGNIFICANT STABLE DRUG DELIVERY 2014
  • Alessi Tomas R.
  • Laski Kennet L.
RU2703471C2
RAPID ACCOMPLISHMENT AND/OR TERMINATION OF SUBSTANTIAL STABLE DRUG DELIVERY 2010
  • Alessi Tomas R.
  • Laski Kennet L.
RU2753280C2
METHOD OF TREATING INSULIN-INDEPENDENT DIABETES AND OBESITY, OSMOTIC DELIVERY SYSTEM AND METHOD FOR MAKING IT 2008
  • Alessi Tomas R.
  • Merser Rajan D.
  • Roloff Katrin M.
  • Jan Bin
RU2440097C2
POLYPEPTIDES SELECTIVE TO GLUCAGON RECEPTORS AND THEIR APPLICATION METHODS 2017
  • Blekuell, Uilyam
  • Srivastava, Ved P.
  • Paulik, Mark A.
  • Yang, Endryu
  • Khanter, Iii, Robert Nil
  • Dok, Stiven Tomas
RU2760007C2
PREVENTING HYPOGLYCAEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS 2012
  • Sil'Vestr Luiz
  • Boka Gabor
  • Miossek Patrik
RU2572703C2
METHOD FOR PREVENTING GLP-1 SIDE EFFECTS 2008
  • Richardson Piter
  • Boumen Robert A.
  • Kostello Donal'D
RU2474415C2
METHOD OF PRODUCING PRODUCTS CONTAINING STABILIZED ACTIVE SUBSTANCES AND COMPOSITIONS CONTAINING THEREOF 2015
  • Ko Sai Ying
RU2702690C2
OCTREOTIDE DELIVERY FROM DRY DOSAGE FORMS 2009
  • Kuzma Petr
  • Deker Stefani
RU2518745C2
LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT 2012
  • Rus Peter
  • Silvestr Luiz
  • Moissek Patrik
  • Penke Zhan-Lui
  • Enselen-Meri Anes
RU2623023C2
PHARMACEUTICAL COMPOSITION 2013
  • Jokhansen Tue
  • Mersebak Khenrietta
  • Akselsen Mads
  • Lange Martin
RU2670106C2

RU 2 547 990 C2

Authors

Alessi Tomas R.

Laski Kennet L.

Dates

2015-04-10Published

2010-09-21Filed